Urogen Pharma earnings were -$113.6M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest URGN earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$33.4M, up 3.5% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, URGN reported annual earnings of -$102.2M, with -6.9% growth. The next URGN earnings date is Nov 12, 2024.
On URGN's earnings call on Invalid Date, Urogen Pharma (NASDAQ: URGN) reported Q2 2024 earnings per share (EPS) of -$0.91, up 11.65% year over year. Total URGN earnings for the quarter were -$33.40 million. In the same quarter last year, Urogen Pharma's earnings per share (EPS) was -$1.03.
The next URGN earnings call is Invalid Date. Add URGN to your watchlist to be reminded of Urogen Pharma's next earnings date.
Is Urogen Pharma profitable or losing money?
As of the last Urogen Pharma earnings report, Urogen Pharma is currently losing money. Urogen Pharma's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$113.58 million, a 4.16% increase year over year.
What was URGN's earnings growth in the past year?
As of Urogen Pharma's earnings date in Invalid Date, Urogen Pharma's earnings has grown year over year. URGN earnings in the past year totalled -$113.58 million.
What are Urogen Pharma's earnings expectations?
The current EPS estimate for Urogen Pharma's earnings report in Invalid Date is -$0.83.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.